Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. owise4eu

OWISE4EU

OWise for Europe - A feasibility study of a pan-European mobile app providing people with cancer with useful tools and treatment information in one easily accessible place.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 OWISE4EU project word cloud

Explore the words cloud of the OWISE4EU project. It provides you a very rough idea of what is the project "OWISE4EU" about.

revenue    validated    stands    licensing    generates    hospital    adjust    prescribed    netherlands    countries    annually    pharmaceutical    patient    quality    70    anonymised    supporting    px    employ    app    award    data    connecting    revenues    medical    collected    reduce    plans    roll    life    analytics    winning    receive    treatment    game    30    business    mobile    diagnosed    platform    first    phases    cancer    bn    126    accurately    gt    visits    owise    uk    people    plan    insurers    pro    incidence    clinical    treatments    engaged    aid    clear    payers    big    least    million    shown    companies    model    groups    independently    expressed    understand    2020    20    interaction    physicians    oncology    initially    reaching    customised    launched    types    clinicians    benefit    health    doctor    issue    care    preferably    changer    insights    breast    worldwide    reported    healthcare    patients    outcome    swiftly    outcomes    actively   

Project "OWISE4EU" data sheet

The following table provides information about the project.

Coordinator		 PX HEALTHCARE BV 

Organization address
address: MUIDERSTRAAT 1
city: AMSTERDAM
postcode: 1011 PZ
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Netherlands [NL]
 Project website https://ec.europa.eu/easme/en/sme/8476/owise-europe-feasibility-study-pan-european-mobile-app-providing-people-cancer-useful-tools
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.4. (Active ageing and self-management of health)
2. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.3.1.6. (Health care provision and integrated care)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-03-01   to  2016-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PX HEALTHCARE BV NL (AMSTERDAM) coordinator 50˙000.00

Map

 Project objective

Cancer is a big issue worldwide with 70% increase in incidence in the next 20 years. Around 3 million people are diagnosed with cancer in Europe annually and it costs the EU more than €126 bn/yr. To improve clinical outcomes of treatments, to reduce side-effects and to increase patients’ quality of life we need to accurately understand how patients experience cancer treatments.

Px HealthCare (also called Px, which stands for Patient Experience) has developed OWise, an independently validated, mobile medical platform supporting cancer patients during treatment. OWise is a real game-changer as - its award-winning app was shown to improve both patient experience and the patient-doctor interaction - while the fully anonymised Patient Reported Outcome data (PRO) are collected and investigated using advanced data-analytics to improve oncology outcomes. As OWise is prescribed by physicians, it is the first oncology platform connecting patients, physicians and payers with the clear potential to benefit all 3 groups. OWise is a novel way for patients to be actively engaged in their treatment and receive customised medical support. It is also a new way for clinicians to receive PRO data and to adjust treatment in between hospital visits. Px’ revenue model is based on licensing insights it generates from the PRO data to health care insurers and pharmaceutical companies who have expressed their great need for it.

Initially launched for breast cancer in the Netherlands and the UK, Px is now developing OWise for all cancer types and plans to employ it swiftly across Europe, preferably with the aid of all 3 Phases of the present programme. Aim of Phase 1 project is to develop of a business plan to roll-out OWise in EU countries, reaching at least 1 million EU cancer patients annually in 2020, providing >20% of these with access to OWise while improving cancer outcomes through its PRO data analysis. Px’ revenues are expected to go up by 30% by 2020, due to this programme.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OWISE4EU" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OWISE4EU" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.4.;H2020-EU.2.1.1.;H2020-EU.2.3.1.;H2020-EU.3.1.6.)

CLINICOVERY (2018)

CLINICOVERY, a versatile, high quality, environmental-friendly, easy to use e-Clinical solution for clinical research

Read More  

SensUS (2018)

SensUS: A non-invasive and quantitative ultrasound (QUS) device for an objective monitoring of the childbirth labour process.

Read More  

ClearRing (2018)

An innovative, minimally invasive medical device used for treatment of Benign Prostatic Hyperplasia symptoms.

Read More